NEUROONE MEDICAL TECHNOLOGIES Corp 8K

NeuroOne Medical Technologies announced successful large-animal procedures using its StereoCED drug delivery platform and expects to recognize related preclinical revenue and launch devices for human investigational use by the end of fiscal Q4 2026.

On August 27, 2026, NeuroOne Medical Technologies Corporation announced the successful completion of three large-animal procedures at the University of Minnesota using its next-generation StereoCED robotic-assisted drug delivery platform, in which its electrodes both delivered a study agent into targeted brain tissue and, in two of the three procedures, recorded intracranial electrophysiological activity from the same regions, a combination the company believes is a first in convection-enhanced delivery. The results are intended to demonstrate technical feasibility and validate the integrated robotic surgical and drug delivery workflow as NeuroOne advances toward the planned launch of StereoCED for human investigational clinical studies later in the current quarter. Development of StereoCED devices for animal use was completed ahead of schedule, enabling earlier-than-expected sales, and the company expects to recognize related revenue from this preclinical research program in fiscal Q4 2026, while development of devices for human investigational use remains on track for release by the end of fiscal Q4 2026.

Filing Facts

CIK

1500198

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-094174

Alert Tier

6